We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Multi-Test Micro-Lab Ready for Clinical Studies

By LabMedica International staff writers
Posted on 05 Aug 2014
Print article
Image: The multi-test micro-lab being developed by Ativa combines multiple detection technologies into a single, low-cost, portable system, now ready for clinical studies (Photo courtesy of Ativa Medical).
Image: The multi-test micro-lab being developed by Ativa combines multiple detection technologies into a single, low-cost, portable system, now ready for clinical studies (Photo courtesy of Ativa Medical).
Developer of a first-of-its-kind micro-lab to help clinicians in almost any setting make earlier treatment decisions, prepares to test the system in clinical studies.

Ativa Medical Corp. (St. Paul, MN, USA) has been developing an innovative micro-lab that incorporates multiple detection methods – allowing many, currently 25, primary blood tests to be performed with a single portable instrument and test cards. It will make critical hematology and chemistry testing affordable for practitioners in healthcare sites around the world. The Ativa micro-lab has advanced to demonstrating equivalence to central lab-based systems that cost many times the price. Ativa will next proceed with clinical studies towards regulatory approval of its tabletop micro-lab for clinical use.

According to a 2014 report by Lab Tests Online, "(Central) laboratory testing is subject to many factors that potentially could adversely affect the integrity of the sample and prevent the timely reporting of an accurate test result." The Ativa system will improve patient experience by reducing time-to-diagnosis and reducing the chances for lab test errors and misdiagnoses as it does not require sample handling by multiple healthcare staff.

The micro-lab is a compact system that combines flow cytometry, electrochemistry, colorimetric testing, and imaging – into a single system. Each test is run on a single, inexpensive, disposable card specifically tailored to the test of choice. The technology, including key microfluidic components, sample preparation, disposable test cards, diagnostic tests and instrumentation, is covered by 80 US patents and 184 patents worldwide. There is currently no single instrument capable of performing the 25 primary blood tests.

Traditional central lab-based testing has not fundamentally changed over the past 30 years. Relying on an external lab for critical tests presents an expensive and time-consuming logistical challenge that means providers in low and mid-volume care settings have no practical solution, forcing physicians to make diagnoses without the data. In much of the developing world there is limited or no access to diagnostic testing due to the prohibitive cost of traditional lab equipment and the lack of medical technicians required to perform the tests.

James M. McNally, PhD, and Ativa's new president and CEO, brings 25-plus years of executive leadership experience in the medical device and diagnostic industry, including most recently serving as vice president of Quest Diagnostics' Products Division, including its point-of-care companies. He has been awarded 12 patents for his healthcare and diagnostic innovations. "In my career, I've had the opportunity to review hundreds of diagnostic instruments and businesses; we believe Ativa's system will be able to deliver central lab quality results in about 5 minutes during a single office visit," said Dr. McNally.

"Ativa's micro-lab, with the footprint of a toaster, will ultimately be able to accurately and efficiently test up to 90% of Medicare's top 30 blood tests," said Dr. McNally, "Ativa's patented disposable microfluidic cards need only a drop of blood yet compete with the quality and consistency of large lab instruments, based on our preclinical complete blood count results. The Ativa system holds great potential where speed-to-diagnosis is critical, such as emergency rooms and urgent care facilities, as well as in private physician offices and retail clinics and pharmacies. Because of the system's affordability and portability, we believe there will be great interest in this system in emerging countries, many of which lack access to quality lab testing of any kind."

The device has not yet been evaluated, cleared, or approved for use by the US FDA; safety and effectiveness have not been established. "Jim McNally's experience with an array of point-of-care products, including navigating commercialization issues and the FDA, gives him important insights to lead Ativa at this stage," said James B. Stake, chairman of Ativa's board of directors, "This system presents a breakthrough product in clinical diagnostics."

Related Links:
Ativa Medical


Flocked Swab
HydraFlock and PurFlock Ultra
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
New
UHF RFID Tag and Inlay
AD-163u8
New
Semi-Automatic Coagulation Analyzer
Clot 2B

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.